Recurrent Ovarian Cancer
Links shared publicly online about this topic
Unique Genetic Marker May Improve Detection Of Recurrent Ovarian Cancer
medicalnewstoday.com — “Ovarian cancer is a major health concern for women and the identification of sensitive biomarkers for early detection and/or monitoring of disease recurrence is of high clinical relevance.” View full resource at medicalnewstoday.com
Most Recently Shared on December 9, 2011 at 9:07 am By:
MNT Ovarian Cancer Health News
Unique Genetic Marker May Improve Detection Of Recurrent Ovarian Cancer http://t.co/7OgdD8rC #ovariancancer
Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer - ONA
oncologynurseadvisor.com — “Amgen announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 7, 2010 at 8:20 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer http://goo.gl/fb/vAkMj
Dr. Karlan Discusses AMG 386 in Recurrent Ovarian Cancer
onclive.com — “Beth Y. Karlan MD Discusses AMG 386 in Recurrent Ovarian Cancer” View full resource at onclive.com
Most Recently Shared on May 5, 2011 at 6:51 pm By:
OncLive TV: Dr. Beth Karlan from @CedarsSinai Discusses AMG 386 in Recurrent Ovarian Cancer http://goo.gl/eO2xa
Oxaliplatin + Doxorubicin in Recurrent Ovarian Cancer Shows Promise, Tolerability - ONA
oncologynurseadvisor.com — “The combination of oxaliplatin and doxorubicin showed promising efficacy in either platinum-sensitive or platinum-resistant recurrent ovarian cancer, as reported by Ilya Pokateav, MD, from the Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, and colleagues at the American Society of Clinical Oncology’s 2011 Annual Meeting.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 5, 2011 at 5:23 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Oxaliplatin + Doxorubicin in Recurrent Ovarian Cancer Shows Promise, Tolerability http://goo.gl/fb/ldXlW
Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer - MPR
empr.com — “Amgen announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.” View full resource at empr.com
Most Recently Shared on June 7, 2010 at 8:14 pm By:
MPR News: Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer: Amgen announced that AMG 386, combin... http://bit.ly/cBbIUj
Bevacizumab Added to Chemotherapy Provides Meaningful Benefit in Recurrent Ovarian Cancer
onclive.com — “Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in PFS when bevacizumab was added to chemotherapy and continued as maintenance therapy.” View full resource at onclive.com
Most Recently Shared on July 27, 2011 at 7:45 pm By:
Bevacizumab Added to Chemotherapy Provides Meaningful Benefit in Recurrent Ovarian Cancer http://t.co/gLOIrDB
Bevacizumab Halves Progression Risk in Recurrent Ovarian Cancer : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on June 5, 2011 at 11:58 pm By:
Miriam E. Tucker Patient Expert
RT @IntMedNews: Bevacizumab Halves Progression Risk in Recurrent Ovarian #Cancer http://bit.ly/ipBNsP
Medical News: ASCO: Trabectedin Useful in Recurrent Ovarian Cancer - in Meeting Coverage, ASCO from MedPage Today
medpagetoday.com — “CHICAGO -- Trabectedin may have a role in the treatment of recurrent ovarian cancer while sparing patients for a time from platinum-based regimens, according to several studies presented here.” View full resource at medpagetoday.com
Most Recently Shared on June 8, 2010 at 5:51 pm By:
ASCO: Trabectedin Useful in Recurrent Ovarian Cancer http://bit.ly/cdzGwZ
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer
blog.mdlinx.com — “The findings of this study are opposite to what would be expected if these markers were good surrogates for treatment benefit.” View full resource at blog.mdlinx.com
Most Recently Shared on August 15, 2011 at 9:51 pm By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer http://t.co/4Kziuul
ChemoFx-assisted chemotherapy reduces treatment costs for recurrent ovarian cancer
news-medical.net — “A study demonstrating the cost savings realized through the use of the ChemoFx® Drug Response Marker for assisting selection of treatment in recurrent ovarian cancer was published recently in the American Journal of Obstetrics and Gynecology (AJOG).” View full resource at news-medical.net
Most Recently Shared on June 4, 2010 at 9:26 am By:
ChemoFx-assisted chemotherapy reduces treatment costs for recurrent ovarian cancer: A study demonstrating the cost... http://bit.ly/bn3YeK
Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent Ovarian Cancer - MPR
empr.com — “Bevacizumab + carboplatin/gemcitabine followed by bevacizumab until disease progression provided a clinically meaningful benefit in women with platinum-sensitive recurrent ovarian cancer, representing the first Phase 3 trial of an antiangiogenic agent to demonstrate such a benefit, investigators reported during the American Society of Clinical Oncology's 2011 Annual Meeting.” View full resource at empr.com
Most Recently Shared on June 5, 2011 at 6:53 pm By:
#asco2011 Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in… http://goo.gl/fb/MUWQq
Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent Ovarian Cancer - ONA
oncologynurseadvisor.com — “Bevacizumab + carboplatin/gemcitabine followed by bevacizumab until disease progression provided a clinically meaningful benefit in women with platinum-sensitive recurrent ovarian cancer, representing the first Phase 3 trial of an antiangiogenic agent to demonstrate such a benefit, investigators reported during the American Society of Clinical Oncology's 2011 Annual Meeting.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 5, 2011 at 6:30 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent… http://goo.gl/fb/oUkM7
ASCO: PARP Inhibitor Slows Recurrent Ovarian Cancer - QualityPoint Technologies
qualitypointtech.net — “CHICAGO (MedPage Today) -- Treatment with an investigational DNA repair inhibitor almost doubled progression-free survival in patients with relapsed, platinum-sensitive ovarian cancer, data from a randomized trial showed.” View full resource at qualitypointtech.net
Most Recently Shared on May 18, 2011 at 11:45 pm By:
ASCO: PARP Inhibitor Slows Recurrent Ovarian Cancer: CHICAGO (MedPage Today) -- Treatment with an investigational ... http://bit.ly/kWiXXK
Updated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer - Drugs.com MedNews
drugs.com — “THOUSAND OAKS, Calif., Amgen (Nasdaq AMGN) today announced AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial invo” View full resource at drugs.com
Most Recently Shared on October 11, 2010 at 11:06 pm By:
Drugs and Devices OW OW Health
Updated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer: THOU... http://bit.ly/b2PL9F #drug
Medical News: ASCO: Debulking Predicts Survival in Recurrent Ovarian Cancer - in Meeting Coverage, ASCO from MedPage Today
medpagetoday.com — “CHICAGO -- The success of primary surgery for ovarian cancer predicted progression-free and overall survival in recurrent disease among patients with at least a 12-month platinum-free interval, data f” View full resource at medpagetoday.com
Most Recently Shared on June 7, 2010 at 3:34 pm By:
ASCO: Debulking Predicts Survival in Recurrent Ovarian Cancer http://bit.ly/a8lAmh
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
MNT Ovarian Cancer
The latest ovarian cancer news published daily. Articles from research centers, universities and prestigious journals.
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
-
Editor
Editors of Oncology & Biotech News/Oncology Net Guide/OncNurse/Contemporary Oncology, on cancer news from pharma, trials, technology, & more.
Advertisement
